Benzinga | Sep 9, 2021 07:19AM EDT

Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients

* Amgen Inc (NASDAQ:AMGN) announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib).

* Lumakras, a KRASG12C inhibitor, is approved in the U.S. for previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

* Related Content: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.

* In a post-hoc analysis of 40 patients, Lumakras achieved a 77.5% disease control rate (DCR), similar to patients without brain metastases.

* A median progression-free survival (PFS) of 5.3 months and median overall survival (OS) of 8.3 months were observed.

* In patients evaluable by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, 14 of 16 patients (88%) maintained intracranial disease control of their stable brain lesions during Lumakras therapy with two achieving complete responses of non-target lesions.

* The safety profile of Lumakras in the brain metastases group was consistent with previous reports.

* Amgen is enrolling patients with active brain metastases in an arm of the CodeBreaK 101 study.

* Price Action: AMGN stock is down 0.41% at $219.97 during the premarket session on the last check Thursday.